Australia - English - Department of Health (Therapeutic Goods Administration)

alnylam australia pty ltd - patisiran, quantity: 10 mg - injection, concentrated - excipient ingredients: peg2000-c-dmg; sodium chloride; dlin-mc3-dma; water for injections; monobasic potassium phosphate; dibasic sodium phosphate heptahydrate; cholesterol; distearoylphosphatidylcholine - onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Israel - English - Ministry of Health

medison pharma ltd - patisiran as sodium - concentrate for solution for infusion - patisiran as sodium 2 mg / 1 ml - patisiran - onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy

European Union - English - EMA (European Medicines Agency)

alnylam netherlands b.v. - patisiran sodium - amyloidosis, familial - other nervous system drugs - onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Canada - English - Health Canada

alnylam netherlands b.v. - patisiran (patisiran sodium) - solution - 2mg - patisiran (patisiran sodium) 2mg - other miscellaneous therapeutic agents

United States - English - NLM (National Library of Medicine)

alnylam pharmaceuticals, inc. - patisiran sodium (unii: wo0ym16lkg) (patisiran - unii:50fkx8cb2y) - onpattro is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. none. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to onpattro during pregnancy. physicians are encouraged to enroll pregnant patients, or pregnant women may register themselves in the program by calling 1-877-256-9526 or by contacting alnylampregnancyprogram@iqvia.com. risk summary there are no available data on onpattro use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. onpattro treatment leads to a decrease in serum vitamin a levels, and vitamin a supplementation is advised for patients taking onpattro. vitamin a is essential for normal embryofetal development; however, excessive levels of vitamin a are associated with adverse developmental effects. the effects on the fetus of a reduction in maternal serum ttr caused by onpattro and of vitamin a supplementation are unknown [see

European Union - English - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - other nervous system drugs - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Canada - English - Health Canada

alnylam netherlands b.v. - vutrisiran (vutrisiran sodium) - solution - 25mg - vutrisiran (vutrisiran sodium) 25mg

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - lopinavir/ritonavir - hiv infections - antivirals for systemic use, - lopinavir/ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infected adults, adolescents and children above the age of 2 years.the choice of lopinavir/ritonavir to treat protease inhibitor experienced hiv-1 infected patients should be based on individual viral resistance testing and treatment history of patients.

United States - English - NLM (National Library of Medicine)

bcm ltd - avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox), octocrylene (unii: 5a68wgf6wm) (octocrylene - unii:5a68wgf6wm), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w) - uses - helps prevent sunburn

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

aj research & pharma sdn. bhd. - desloratadine -